MedAbome
San Francisco, Israel· Est.
Innovative antibody discovery platform delivering first‑in‑class therapeutics for unmet oncology and immune indications.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Innovative antibody discovery platform delivering first‑in‑class therapeutics for unmet oncology and immune indications.
OncologyImmunology
Technology Platform
Proprietary Live‑Cell Immunization (LC‑I) combined with Live‑Cell High‑Throughput Screening (LC‑HTS) to generate high‑affinity, conformational‑epitope‑specific antibodies using hybridoma technology.
Opportunities
The platform can rapidly generate antibodies against previously undruggable targets, creating opportunities for partnerships with pharma companies seeking novel oncology and immunology therapeutics.
Risk Factors
Pre‑clinical stage with no IND filings; success depends on translating platform discoveries into clinically viable candidates and securing funding.
Competitive Landscape
Competes with other antibody discovery platforms; differentiation lies in live‑cell immunization and high‑throughput screening that target native conformational epitopes.